Net income increased 11% to $29.6 million driven by strong top-line growth.
EBITDA margin expanded to 28.4% from 27.3% due to higher billing rates.
Aggressive return of capital with $78.8M in repurchases and a new $50M authorization.
Total operating income fell 6.9% as compensation expenses surged 20.4%.
Exponent's first quarter presents a stark dichotomy between top-line growth and cash-flow sustainability. On one hand, the company is successfully capturing the 'AI tailwind,' with revenues climbing 14.3% and EBITDA margins expanding slightly. The growth in the Engineering and Other Scientific segment proves that the firm's specialized expertise remains in high demand as companies navigate complex technological and regulatory landscapes. However, the financial cost of this growth is evident in the negative operating cash flow and the rapid depletion of the balance sheet. The reliance on treasury stock purchases to inflate diluted EPS, combined with a slump in the Environmental and Health segment, suggests that the operational efficiency is not keeping pace with the scale. Investors must now weigh the ability of the firm to maintain its premium valuation against a shrinking cash runway and rising corporate overhead.